<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="73836">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01868243</url>
  </required_header>
  <id_info>
    <org_study_id>DAWA2013</org_study_id>
    <nct_id>NCT01868243</nct_id>
  </id_info>
  <brief_title>Dabigatran Versus Warfarin After Mitral and/or Aortic Bioprosthesis Replacement and Atrial Fibrillation Postoperatively</brief_title>
  <acronym>DAWA</acronym>
  <official_title>Dabigatran Versus Warfarin After Mitral and Aortic Bioprosthesis Replacement for the Management of Atrial Fibrillation Postoperatively: Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Ana Nery</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Ana Nery</source>
  <oversight_info>
    <authority>Brazil: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized open study (pilot study) was designed to compare twice-daily oral Dabigatran
      with dose-adjusted warfarin for the prevention of stroke (ischemic or hemorrhagic) and
      systemic embolism in persistent or permanent atrial fibrillation after bioprosthesis
      replacement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Between the period of August 2013 to July 2014, 100 patients with chronic rheumatic valve
      disease undergoing bioprosthetic valve replacement (mitral and/or aortic) in the cardiology
      service of Hospital Ana Nery in Salvador - Brazil, with persistent or permanent atrial
      fibrillation postoperatively will be selected to this randomized open pilot study.

      By a process of simple randomization, half (50 patients) will use for 3 to 6 months of
      Dabigatran, and other half will use warfarin (the same period). Episodes of ischemic or
      hemorrhagic stroke, thromboembolism and bleeding (major and minor) will be closely observed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Embolic Events</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The primary efficacy end point was the composite of stroke (ischemic or hemorrhagic) and systemic embolism.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Major or minor bleeding. An individual occurrence of stroke, systemic embolism, or death from all causes.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Primary Disease</condition>
  <arm_group>
    <arm_group_label>Dabigatran</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dabigatran 110 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Warfarin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Warfarin adjusted-dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran</intervention_name>
    <description>Group 1 - Dabigatran 110 mg (50 patients)</description>
    <arm_group_label>Dabigatran</arm_group_label>
    <other_name>PradaxaÂ® (dabigatran etexilate) 110mg twice daily</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Warfarin adjusted-dose</description>
    <arm_group_label>Warfarin</arm_group_label>
    <other_name>Warfarin adjusted-dose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients between 18 and 64 years, with chronic rheumatic valvular disease after
             bioprosthesis replacement with permanent or persistent atrial fibrillation will be
             eligible;

        Exclusion Criteria:

          -  Previous stroke (ischemic or hemorrhagic)

          -  Severe renal impairment (creatinine clearance rates &lt;30 ml/mn);

          -  active liver disease;

          -  increased risk of bleeding;

          -  uncontrolled hypertension;
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andre R Duraes, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Ana Nery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andre R Duraes, PhD</last_name>
    <phone>0557191888399</phone>
    <email>andreduraes@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Ana Nery</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <zip>40320010</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andre R Duraes</last_name>
      <phone>0557191888399</phone>
      <email>andreduraes@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Andre R Duraes</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bianca A Nunes</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juliana QV Muniz</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pollianna S Roriz</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Italvar NC Neto</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roque A Junior</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet. 2006 Sep 16;368(9540):1005-11.</citation>
    <PMID>16980116</PMID>
  </reference>
  <reference>
    <citation>Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis. 2005 Nov;5(11):685-94. Review. PubMed PMID: 16253886.</citation>
    <PMID>16253886</PMID>
  </reference>
  <reference>
    <citation>Sun JC, Davidson MJ, Lamy A, Eikelboom JW. Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends. Lancet. 2009 Aug 15;374(9689):565-76. doi: 10.1016/S0140-6736(09)60780-7. Review.</citation>
    <PMID>19683642</PMID>
  </reference>
  <reference>
    <citation>Heras M, Chesebro JH, Fuster V, Penny WJ, Grill DE, Bailey KR, Danielson GK, Orszulak TA, Pluth JR, Puga FJ, et al. High risk of thromboemboli early after bioprosthetic cardiac valve replacement. J Am Coll Cardiol. 1995 Apr;25(5):1111-9.</citation>
    <PMID>7897124</PMID>
  </reference>
  <reference>
    <citation>Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sep 17;361(12):1139-51. Epub 2009 Aug 30.</citation>
    <PMID>19717844</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 5, 2013</lastchanged_date>
  <firstreceived_date>May 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Ana Nery</investigator_affiliation>
    <investigator_full_name>Andre Duraes, PhD</investigator_full_name>
    <investigator_title>Andre Rodrigues Duraes</investigator_title>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Bioprosthesis</keyword>
  <keyword>Stroke</keyword>
  <keyword>Dabigatran</keyword>
  <keyword>Warfarin</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
